Evrofarma SA (EVROF) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Evrofarma SA stock €4.82, price €3.65, upside +32.1%, quality 51 out of 100. Rating: undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range €0.6355 – €4.31 · fair‑value band €3.37 – €6.26 · the €3.65 price screens below the €4.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Evrofarma in your weekly email
Every Wednesday you see whether Evrofarma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products. Evrofarma SA was founded in 1991 and is headquartered in Didymoteicho, Greece.
Stock analysis
Evrofarma SA (EVROF) currently trades at €3.65, while our model-based Fair Value estimate is €4.82, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €4.82 per share, and 7 of the 14 models we run sit above the €3.65 price.
Bear case: the Asset-Based group reads lowest at €1.00, and 7 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €3.37 (bear) to €6.26 (bull), the price of €3.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Evrofarma SA reported revenue of €49.4M in FY2025 versus €36.7M in FY2021, a compound +7.7%/yr. Reported net income was €3.5M in FY2025.
Key figures
Market cap €49.9M Micro · P/E ratio 46.2 · P/S ratio 3.29 · EPS (TTM) €0.0790 · Dividend yield 1.6% · Net margin 7.1% · Return on equity 20.2% · Return on assets (EBIT) 5.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 32%, EVROF screens cheaper than that median.
Fair Value models
Bear€3.37Fair Value €4.82Bull€6.26
Price €3.65 · Upside +32.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0163 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Start year 2020 (pandemic). Over 10 years: +5.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+28.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.7%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.41.7% vs 22.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 8%
2025 sits 60% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+32.1% · Above median
Profitability
Return on equity (12 months)20.2% · Top 25%
Return on assets6.3% · Above median
Net margin (12 months)8.4% · Above median
Operating margin (12 months)12.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)8.8% · Above median
Dividend yield (12 months)1.6% · Below median
Balance sheet
Debt / equity0.78× · Highest 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Evrofarma SA Fair Value". https://www.fairvalue-calculator.com/stock/EVROF
Frequently asked questions
Is Evrofarma SA (EVROF) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €4.82 versus a price of €3.65, about +32% upside (undervalued).
What is the fair value of EVROF?
Our model-based fair value for Evrofarma SA is €4.82 (as of Nov 9, 2026), built from audited fundamentals. The current price: €3.65.
What is the quality score of EVROF?
Evrofarma SA has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evrofarma SA (EVROF)?
Our model-based price target is the fair value of €4.82 (as of Nov 9, 2026) from 14 valuation models. Cautious scenario €3.37, optimistic scenario €6.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Evrofarma SA stock forecast for 2026?
Our models put fair value at €4.82, about +32% upside versus a price of €3.65 (undervalued). Cautious scenario €3.37, optimistic scenario €6.26. The calculation is refreshed regularly with new filings.
What is the revenue of Evrofarma SA (EVROF)?
Evrofarma SA reported trailing-twelve-month revenue of about €51.6M (latest available figure, as of Nov 9, 2026).
Does Evrofarma SA pay a dividend?
Evrofarma SA currently shows a dividend yield of 1.64% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Evrofarma SA (EVROF) and when is the ex-dividend date?
Evrofarma SA pays a dividend of €0.06 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Sep 15, 2026. The payout ratio is 75.9% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Evrofarma SA (EVROF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evrofarma SA it is €4.82 per share (as of Nov 9, 2026), against a price of €3.65. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Evrofarma SA stock overvalued or undervalued in 2026?
As of Nov 9, 2026, EVROF trades below its calculated fair value: price €3.65, fair value €4.82, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVROF?
No. The price is what the market pays today (€3.65); the fair value is what the company's own numbers justify (€4.82). For Evrofarma SA the two are €1.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evrofarma SA worth?
The market values Evrofarma SA at about €49.9M (market capitalisation, as of Nov 9, 2026). Per share that is €3.65; our models calculate a fair value of €4.82 per share.
What do the bullish and bearish scenarios say about EVROF?
Our models span a range for Evrofarma SA: cautious scenario €3.37, base €4.82, optimistic €6.26 per share (as of Nov 9, 2026, price €3.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EVROF?
Evrofarma SA trades at a price-to-earnings ratio of 46.2 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €4.82 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 9.0. Other multiples: P/B 2.7, P/S 1.1, EV/EBITDA 8.7.
How solid is the balance sheet of Evrofarma SA (EVROF)?
Balance-sheet figures for Evrofarma SA (as of Nov 9, 2026): return on equity 20.2%, debt of 0.78 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is EVROF from its 52-week high?
Evrofarma SA trades at €3.65, about 15% below its 52-week high of €4.31 and 38% above the low of €2.65 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €4.82 is for.
Which stocks are comparable to Evrofarma SA?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evrofarma SA stock attractive at the current price?
The data as of Nov 9, 2026: price €3.65, calculated fair value €4.82 (+32%), Quality Score 51/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVROF calculated?
We run Evrofarma SA through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €4.82 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Evrofarma SA currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evrofarma SA (EVROF)?
The closing price on Nov 6, 2026 was €3.65. Our model-based fair value is €4.82, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evrofarma SA right now?
Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (€3.37 to €6.26) leaves room in how you read the outcome.
Where does the earnings growth of Evrofarma SA (EVROF) come from?
Earnings per share at Evrofarma SA grew +22.7 % a year from 2015 to 2025. Broken into its drivers: revenue per share +6.0 %, EBIT margin −0.9 %, tax rate +6.7 %, residual (interest, one-offs) +9.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Evrofarma SA
How large is the market capitalisation of Evrofarma SA (EVROF)?
The market capitalisation of Evrofarma SA is €49.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evrofarma SA (EVROF)?
The price-to-sales ratio of Evrofarma SA is 3.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evrofarma SA (EVROF)?
Earnings per share at Evrofarma SA are €0.0790 (price ÷ EPS = P/E 46.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Evrofarma SA (EVROF)?
The dividend yield of Evrofarma SA is 1.6% (payout 75.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Evrofarma SA (EVROF)?
The net margin of Evrofarma SA is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evrofarma SA (EVROF)?
The return on equity (ROE) of Evrofarma SA is 20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evrofarma SA (EVROF)?
On an EBIT basis the return on assets of Evrofarma SA is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evrofarma SA (EVROF)?
The operating margin of Evrofarma SA is 12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evrofarma SA (EVROF)?
Revenue at Evrofarma SA is growing +8.8% versus a year earlier (3y avg +2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Evrofarma SA (EVROF)?
Earnings per share at Evrofarma SA are growing +44.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Evrofarma SA (EVROF) generate?
The free cash flow of Evrofarma SA is −€509K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evrofarma SA (EVROF) carry?
The net debt of Evrofarma SA is €10.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Evrofarma SA in the live analysis
One click puts Evrofarma SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026